It's no secret that capital spending budgets are falling at oil companies across the globe, but that's not the case for this company, writes MoneyShow's Jim Jubak, who points out the efficiency measures and new technology products responsible for much of its success.
Everyone knows that capital spending budgets at the world's oil companies are falling.
But it just doesn't seem to matter for Schlumberger (SLB). Schlumberger is a member of my Jubak's Picks portfolio.
On January 17, the oil services and technology company reported fourth quarter earnings of $1.35 a share, beating Wall Street estimates by two cents a share. Earnings grew by 29.8% year over year.
Revenue climbed 7.4% year over year to $11.91 billion. That was slightly below the $11.98 projected by Wall Street.
I think you can tell what's going on at Schlumberger simply by taking a glance at those earnings and revenue growth rates. Revenue growth is indeed sluggish in the oil field. But Schlumberger's margins are climbing, thanks to efficiencies at the company and, especially, thanks to its years of investment in oil field technologies.
5 Best Cheap Stocks To Buy For 2015: Thompson Creek Metals Company Inc.(TC)
Thompson Creek Metals Company Inc., through its subsidiaries, engages in mining, milling, processing, and marketing molybdenum products in the United States and Canada. The company?s principal properties include the Thompson Creek Mine and mill in Idaho; a metallurgical roasting facility in Langeloth, Pennsylvania; and a joint venture interest in the Endako Mine, mill, and roasting facility in British Columbia. It also holds interests in development projects comprising the Davidson molybdenum property and the Berg copper-molybdenum-silver property located in northern British Columbia; the Howard?s Pass property, a lead and zinc project situated in the Yukon territory-northwest territories border; and the Maze Lake property, a gold project located in the Kivalliq district of Nunavut. The company produces molybdenum products, primarily molybdic oxide and ferromolybdenum, as well as soluble technical oxide, pure molybdenum tri-oxide, and high purity molybdenum disulfide. As o f December 31, 2010, its consolidated recoverable proven and probable ore reserves totaled 462.2 million pounds of contained molybdenum in the Thompson Creek Mine and the Endako Mine. The company was formerly known as Blue Pearl Mining Ltd. and changed its name to Thompson Creek Metals Company Inc. in May 2007. Thompson Creek Metals Company Inc. is based in Denver, Colorado.
Advisors' Opinion:- [By Jon C. Ogg]
Thompson Creek Metals Co. Inc. (NYSE: TC) was at 54% discount to its book value of $8.30 per share at the time, and the stock price of $3.90 is up from $3.03 Deutsche Bank’s team nailed upside of more than 28% here. Its price target was $4 at the time versus a consensus target of $4.50 at the time. The 52-week range here is $2.42 to $4.55, but we would point out that the consensus price target is $3.93.
Best Oil Service Companies To Buy Right Now: Revett Mining Company Inc (RVM)
Revett Mining Co Inc, formerly Revett Minerals Inc., is a silver-copper producer. The Company owns and operates the producing Troy Mine and the development-stage Rock Creek project; both properties are located in northwestern Montana. Troy is an underground copper and silver mine. Rock Creek is a development-stage underground copper and silver project. Revett Silver owns all of Troy and Rock Creek through two wholly owned Montana subsidiaries, Troy Mine Inc. and RC Resources Inc., respectively. Rock Creek is located in Sanders County, Montana, approximately 5 miles northeast of the town of Noxon. The Troy Mine is located in Lincoln County, Montana. During the year ended December 31, 2011, RC Resources Inc. acquired eight claims (the JE claims) and staked an additional 200 claims (the Lost Girl claims) northwest of Rock Creek increasing the property position at Rock Creek by approximately 4,000 acres. Advisors' Opinion:- [By James E. Brumley]
If you've never heard of Revett Minerals Inc. (NYSEMKT:RVM) before right now, don't worry about it - you're not alone. The $25 million silver and copper miner doesn't have enough size to merit much media attention, and to make things more difficult, silver and miner has spent the better part of 2013 being out of favor. Yet, things are slowing changing for RVM and its shareholders.... for the better. Though a little more work needs to be done, this stock's knocking on the door of a monster breakout.
Best Oil Service Companies To Buy Right Now: Titan Pharmaceuticals Inc (TTNP)
Titan Pharmaceuticals, Inc., incorporated in February 1992, is a biopharmaceutical company developing therapeutics primarily for the treatment of central nervous system (CNS) disorders. The Company is focused primarily on clinical development of products that include Probuphine for the treatment of opioid addiction; Iloperidone: for the treatment of schizophrenia and related psychotic disorders, and Spheramine for the treatment of advanced Parkinson�� disease. Titan Pharmaceuticals is directly developing its product candidates and also utilizing corporate partnerships, including a collaboration with Bayer Schering Pharma AG, Germany (Bayer Schering) for the development of Spheramine to treat Parkinson�� disease, and Vanda Pharmaceuticals, Inc. (Vanda) for the development of iloperidone for the treatment of schizophrenia and related psychotic disorders.
Probuphine
Probuphine is the first product to utilize the Company�� ProNeura long-term drug delivery technology. Probuphine is designed to provide continuous, long-term therapeutic levels of the drug buprenorphine, an approved agent for the treatment of opioid addiction. In December 2007, the Company completed enrollment in a randomized, double-blind, placebo-controlled, multi-center Phase III clinical study of Probuphine in the treatment of opioid addiction. This 150 patient study, which is being conducted in the United States, will evaluate the safety and effectiveness of treatment with Probuphine versus placebo in reducing opioid addiction over 24 weeks of treatment. This study is part of a registration directed program intended to obtain marketing approval of Probuphine for the treatment of opioid addiction in Europe and the United States.
Iloperidone
Iloperidone was evaluated in a Phase III program comprising over 3,500 patients at more than 200 sites in 24 countries, administered and funded by Novartis Pharma AG (Novartis). In three completed efficacy studies conducted by Novartis, ilop! eridone statistically reduced the symptoms of schizophrenia compared to placebo. Iloperidone has also been investigated in three 12-month safety studies, which confirm safety and tolerability. A dose dependent increase in the Q-T Corrected (QTc) interval was observed and investigated further in a clinical study, and no clinically significant adverse events were observed. In September 2007, Vanda submitted a new drug application (NDA) with the United States Food and Drug Administration (FDA) for iloperidone. The NDA for iloperidone was officially accepted for review by the FDA in November 2007.
Spheramine
Spheramine is a cell-based therapeutic that utilizes the Company�� cell-coated microcarrier (CCM) technology, which enables the development of cell-based therapies for minimally invasive, site-specific delivery to the central nervous system of therapeutic factors precisely where they are needed. Spheramine consists of microcarriers coated with human retinal pigment epithelial cells that are intended to enhance brain levels of dopamine, a neurotransmitter deficient in certain brain regions in Parkinson�� disease, leading to movement disorders. Preclinical studies have demonstrated the preliminary efficacy and safety of Spheramine, including blinded studies in a primate model of Parkinson�� disease. In June 2007, enrollment was completed in a current multi-center, randomized, double-blind, placebo-controlled clinical trial of Spheramine in Parkinson�� disease. This Phase IIb clinical study enrolled 71 patients with advanced Parkinson�� disease (Hoehn and Yahr Stages III and IV) to further evaluate the efficacy, safety, and tolerability of Spheramine.
Bayer Schering, the Company�� corporate partner for worldwide development and commercialization of Spheramine, is funding the clinical development program for Spheramine. Under an agreement, Bayer Schering has received exclusive, worldwide development, manufacturing and commercialization rights, and, in ad! dition to! the clinical and manufacturing development funding and milestone payments, Bayer Schering will pay Titan Pharmaceuticals a royalty on future product sales.
Advisors' Opinion:- [By CRWE]
Today, TTNP surged (+2.76%) up +0.018 at $.689 with 152,996 shares in play thus far (ref. google finance Delayed: 2:02PM EDT October 1, 2013).
Titan Pharmaceuticals, Inc. previously reported that the U.S. Food and Drug Administration (FDA) has granted the request for a meeting to discuss Probuphineåº. The meeting is scheduled for November 19, 2013. The FDA has designated this as a Type C meeting and has requested the submission of briefing materials by October 7, 2013.
Best Oil Service Companies To Buy Right Now: Enzo Biochem Inc. (ENZ)
Enzo Biochem, Inc., an integrated life sciences and biotechnology company, engages in the research, development, manufacture, and marketing of diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. The company operates in three segments: Clinical Labs, Life Sciences, and Therapeutics. The Clinical Labs segment offers routine and esoteric clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition. This segment operates a full-service clinical laboratory, a network of approximately 30 patient service centers, a laboratory, and a full-service phlebotomy and in-house logistics department. The Life Sciences segment manufactures, develops, and markets products and tools to life sciences, drug development, and clinical research customers. It provides proteins, antibodies, peptides, small molec ules, labeling probes, dyes, and kits, which offer tools for target identification/validation, high content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis to life science researchers. This segment provides its products to scientific experts primarily in the field of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Therapeutics segment researches and develops therapeutic drug candidates in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. The company sells its products through its direct sales force; and a network of distributors worldwide. Enzo Biochem, Inc. was founded in 1976 and is headquartered in New York, New York.
Advisors' Opinion:- [By CRWE]
Enzo Biochem Inc. (NYSE:ENZ) is a pioneer in molecular diagnostics, leading the convergence of clinical laboratories, life sciences and therapeutics through the development of unique diagnostic platform technologies that provide numerous advantages over previous standards.
Best Oil Service Companies To Buy Right Now: Sirius XM Radio Inc.(SIRI)
Sirius XM Radio Inc. provides satellite radio services in the United States and Canada. It broadcasts a programming lineup of approximately 135 channels of commercial-free music, sports, news and information, talk and entertainment, traffic, and weather on subscription fee basis through two satellite radio systems in the United States; and holds an interest in the satellite radio services offered in Canada. The company also simulcasts music and selected non-music channels over the Internet; and offers applications to allow consumers to access its Internet services on mobile devices. As of December 31, 2010, it had 20,190,964 subscribers. In addition, the company designs, establishes specifications, sources or specifies parts and components, and manages various aspects of the logistics and production of satellite radios; licenses its technology to various electronics manufacturers to develop, manufacture, and distribute radios under various brands; and imports radios distri buted through its Websites. The company?s satellite radios are primarily distributed through automakers, retailers, and its Websites. Further, it provides music services for commercial establishments; a satellite television service to offer music channels as part of certain programming packages on the DISH Network satellite television service; music and comedy channels to mobile phone users through mobile phone carriers; Backseat TV, a service offering television content designed primarily for children in the backseat of vehicles; Travel Link, a suite of data services that include graphical weather, fuel prices, sports schedules and scores, and movie listings; and real-time traffic and weather services. The company was formerly known as Sirius Satellite Radio Inc. and changed its name to Sirius XM Radio Inc. in August 2008. Sirius XM Radio Inc. was founded in 1990 and is headquartered in New York, New York.
Advisors' Opinion:- [By Rick Munarriz]
Investors continue to warm up to Sirius XM Radio (NASDAQ: SIRI ) , and that's bad news for those holding the 380.3 million shares sold short.
- [By Jonas Elmerraji]
2013 has been a strong year for Sirius XM Radio (SIRI) -- the satellite radio company has seen its shares rally more than 30% since the calendar flipped over to January, more than doubling the S&P's ascent year-to-date. Sirius XM provides subscription-based radio coverage to more than 25 million subscribers in the U.S. and Canada. Beyond satellite, Sirius has made big investments in its online platform of late, adding options like on demand programming to the mix.
The breakneck growth of auto sales in 2013 is trickling down to SIRI's income statement. With satellite radio transmitters installed in more than two-thirds of new cars sold today, the firm has a captive audience that's excited to play with the features of their latest big purchases, including free trials to SIRI's services. As a result, the firm converts close to half of those trial users into paying subscribers. Size matters in the content business, and Sirius XM's scale means that the firm can afford to pay for exclusive names and pricey content partnerships for sports and music.
Even though rivals like Pandora (P) are competing to grab consumers' drive-time attention (and dollars), SIRI's dominant integration and superior service coverage gives it a major advantage in the shootout.
- [By Rick Munarriz]
In this video, longtime Fool contributor Rick Munarriz goes over three aspects of iTunes Radio that should alarm Pandora investors -- and one of them should also spook Sirius XM Radio (NASDAQ: SIRI ) shareholders.
- [By Crunching Numbers]
One of the more frequent questions asked recently about Sirius XM Radio (SIRI) is "With all the good news about this company, why hasn't the price moved higher?" Another common question is about whether or not Sirius XM or its majority shareholder, Liberty Media (LMCA), are somehow holding the price down by not disclosing information.
Best Oil Service Companies To Buy Right Now: FirstEnergy Corporation(FE)
Firstenergy Corp. operates as a diversified energy company. The company, through its subsidiaries and affiliates, involves in the generation, transmission, and distribution of electricity, as well as energy management and other energy-related services. It serves approximately 6 million customers within 67,000 square miles through 10 utility operating companies in Ohio, Pennsylvania, New Jersey, West Virginia and Maryland. The company was founded in 1996 and is headquartered in Akron, Ohio.
Advisors' Opinion:- [By Justin Loiseau]
Investors might invest in a good company with solid returns -- but is it the place where their hard-earned profits are best spent? Let's compare big dividend-dealing utilities FirstEnergy (NYSE: FE ) and Consolidated Edison (NYSE: ED ) , to see where we should stash our cash.
- [By Justin Loiseau]
Cutting back on coal
Both Duke Energy stock and AEP stock have long relied on coal, clean or not, to power their profits. But some historically coal-centric utilities are calling it quits. FirstEnergy (NYSE: FE ) counts on coal for around 64% of its total generation capacity�and had to idle several of its power plants last year as cheap natural gas prices and EPA regulations cut out coal's competitiveness. In early 2012, the utility announced plans to retire a whopping 3,400 MW of coal-fired power generation, more than a quarter of its current capacity.� - [By Johanna Bennett]
FirstEnergy (FE) fell 5.7%. The power company last week narrowed its full-year outlook.
Denbury Resources (DNR) shares dropped 5.9% after oil-and-natural-gas explorer on Sunday announced that it will initiate quarterly dividend and raised its share repurchase plan to $250 million from the $109 million remaining in its program.
- [By John Divine]
Of course, Exelon isn't the only utilities company that stands to be hit by the changes ahead in energy markets. FirstEnergy (NYSE: FE ) ended as the second-largest decliner, falling 6.5% on similar concerns as the stock was downgraded by Credit Suisse from outperform to neutral. The utilities sector was the lone major sector of the market to slip today, so it's not shocking to see two of the day's largest laggards originating from that area.
No comments:
Post a Comment